Becoming a Drug Discovery Company under the Long-Term Management Vision 2025 and Medium-Term Management Plan 2022
First written in FY2021-Q1. 12 of 17 entries say "Restated". Latest entry: 2026-05-13.
Takara Bio moved to the "Worse" side of this theme in 2026.
The whole theme swung hardest in 2023: 1 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Softened".
- FY2026-H1RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Vision 2025 and the three-year Medium-Term Management Plan 2025, both ending in fiscal 2025, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a global platform company supporting the infrastructure of the life sciences industry.」
経営方針・経営戦略等について重要な変更はないとし、長期経営構想2025・中期経営計画2025のもとで、試薬・機器事業とCDMO事業を通じた創薬基盤技術開発およびグローバルプラットフォーマー化を継続している。 - FY2025-H1RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Vision 2025 and the three-year Medium-Term Management Plan 2025, both ending in fiscal 2025, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a global platform company supporting the infrastructure of the life sciences industry.」
長期経営構想2025・中期経営計画2025に基づく創薬基盤技術開発およびグローバルプラットフォーマー化の方針を継続している。 - FY2024SoftenedAnnual report
「当社グループは、「中期経営計画2025」最終年度である、2025年度の定量目標（連結営業利益150億円、ROE８％以上）達成を目指しておりますが、現下の経営環境においては、その目標達成のハードルは大変高いものと認識しております。」
営業利益150億円・ROE8％以上の2025年度目標は維持しているが、現下の環境では達成のハードルが高いとの認識を追加している。 - FY2024-Q3RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Vision 2025 and the three-year Medium-Term Management Plan 2025, both ending in fiscal 2025, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a global platform company supporting the infrastructure of the life sciences industry.」
中期経営計画2025のもと、試薬・機器事業とCDMO事業を通じた創薬基盤技術開発およびグローバルプラットフォーマー化を継続している。 - FY2024-Q2RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Vision 2025 and the three-year Medium-Term Management Plan 2025, both ending in fiscal 2025, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a global platform company supporting the infrastructure of the life sciences industry.」
中期経営計画2022から更新された中期経営計画2025のもと、試薬・機器事業とCDMO事業を通じた創薬基盤技術開発およびグローバルプラットフォーマー化を継続している。 - FY2024-Q1RestatedAnnual report
「Against this backdrop, under the six-year Long-Term Management Concept 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2025, ending in fiscal 2025, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Reagents and Instruments business and CDMO business, with the aim of becoming a global platform company supporting the infrastructure of the life sciences industry.」
中期経営計画2022から中期経営計画2025へ更新された実行計画のもと、創薬基盤技術開発とグローバルプラットフォーマー化を進める方針を継続している。 - FY2023RaisedAnnual report
「「中期経営計画2025」の概要 （１） 期間 2023年度～2025年度（3年間） （２） 全体方針 「長期経営構想2025」の定量目標を前倒し、飛躍的成長を成し遂げる （３） 計画最終年度定量目標 営業利益150億円、ROE８％以上」
長期経営構想2025の定量目標を前倒しする中期経営計画2025を策定し、2025年度の営業利益目標を150億円、ROEを8％以上とした。 - FY2023-Q3RestatedAnnual report
「Under the six-year Long-Term Management Vision 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a drug-discovery company that continuously creates new modalities.」
長期経営構想2025および中期経営計画2022に基づく創薬企業化の方針を継続している。 - FY2023-Q2RestatedAnnual report
「Under the six-year Long-Term Management Vision 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a drug-discovery company that continuously creates new modalities.」
長期経営構想2025および中期経営計画2022に基づく創薬企業化の方針を継続している。 - FY2023-Q1RestatedAnnual report
「Under the six-year Long-Term Management Vision 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group advanced the development of core technologies for biopharmaceutical drug discovery through the Reagents and Instruments Business and the CDMO Business, pursuing initiatives to become a drug-discovery company that continuously creates new modalities.」
長期経営構想2025および中期経営計画2022に基づく創薬企業化の方針を継続している。 - FY2022-Q3RestatedAnnual report
「Under the six-year Long-Term Management Concept 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Reagents and Instruments business and Contract Development and Manufacturing Organization (CDMO) business, with the aim of becoming a drug-discovery company that continuously creates new modalities.」
長期経営構想2025および中期経営計画2022に基づく創薬企業化の方針を継続している。 - FY2022-Q2RestatedAnnual report
「Under the six-year Long-Term Management Concept 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Reagents and Instruments business and Contract Development and Manufacturing Organization (CDMO) business, with the aim of becoming a drug-discovery company that continuously creates new modalities.」
長期経営構想2025・中期経営計画2022に基づく創薬企業化の方針を継続している。 - FY2022-Q1RestatedAnnual report
「Under the six-year Long-Term Management Concept 2025, ending in fiscal 2025, and the three-year Medium-Term Management Plan 2022, ending in fiscal 2022, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Reagents and Instruments business and Contract Development and Manufacturing Organization (CDMO) business, with the aim of becoming a drug-discovery company that continuously creates new modalities.」
長期経営構想2025・中期経営計画2022に基づく創薬企業化の方針を継続している。 - FY2021-Q2RestatedAnnual report
「Against this backdrop, under its corporate philosophy, “We contribute to people’s health through the development of innovative biotechnologies, including gene therapy,” and the newly formulated Long-Term Management Concept 2025 and Medium-Term Management Plan 2022, the Group pursued initiatives to develop bio-drug-discovery platform technologies through its Research Reagents and Scientific Instruments business and CDMO business, with the aim of becoming a drug-discovery company that continuously creates new modalities.」
長期経営構想2025・中期経営計画2022に基づく創薬企業化の方針に重要な変更はない。 - FY2021-Q1First statedAnnual report
「Under the newly formulated Long-Term Management Vision 2025 and Medium-Term Management Plan 2022, the Group advanced initiatives to develop core biotechnology platforms for drug discovery through its research reagents and scientific instruments business and CDMO business, with the aim of becoming a drug discovery company that continuously creates new modalities.」
First disclosed the policy of formulating Long-Term Management Vision 2025 and Medium-Term Management Plan 2022 and becoming a drug discovery company through the research reagents and scientific instruments business and CDMO business.